Begonia: The innovative drug APH03571 tablet of the wholly-owned subsidiary has obtained the clinical trial approval letter.

Announcement of Yipin Hong: The drug clinical trial application for the innovative drug APH03571 tablet independently developed by its wholly-owned subsidiary, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration, and the "Notice of Approval for Drug Clinical Trial" has been received. The clinical trial will be conducted in the near future.